Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ World https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Russia approves second Covid-19 vaccine after preliminary tests

Russia approves second Covid-19 vaccine after preliminary tests



Russia has said it will produce thousands of coronavirus vaccines a month before the end of the year.

Karol Smilyan NurPhoto | Getty Images

Russia has issued regulatory approval for a second Covid-19 vaccine, according to its registry of authorized drugs.

Admired President Vladimir Putin announced the news at a government meeting on Wednesday.

The strike was developed by the Vector Institute in Siberia and completed an early stage of human experiments last month. However, the results have not yet been published and a large-scale study known as phase III has not yet begun.

“We need to increase production of the first and second vaccines,”

; Putin said in comments broadcast on state television.

“We continue to work with our foreign partners and will promote our vaccine abroad.”

The peptide-based vaccine, called EpiVacCorona, is the second to be licensed for use in Russia. There is a placebo-controlled study on 100 volunteers between the ages of 18 and 60 in Novosibirsk.

A shot developed by Moscow’s Gamaleya Institute, Sputnik V, was licensed for home use in August.

This vaccine, based on an adenoviral vector, was also registered before the phase III trials. A trial of 40,000 participants is currently underway in Moscow.

The large-scale human trial of EpiVacCorona is likely to begin in November or December, TASS reported this month, quoted by consumer safety supervisor Rospotrebnadzor, which controls the institute.

It is expected that 30,000 volunteers will be involved in the process, of which the first 5,000 will be residents of Siberia, Interfax reported.

According to the Ministry of Health, hundreds of people in occupations that put them at high risk for coronavirus infection have already received Gamaleya jab, but the vaccine is not yet in common use.

Since the beginning of the pandemic, Russia has registered more than 1,340,000 infections, the fourth in the world after the United States, India and Brazil.

Another vaccine against Covid-19 is being developed by the Chumakov Institute in St. Petersburg. It plans to begin an early phase of a clinical trial involving about 300 people on October 19th.


Source link